Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes

Archives of Internal Medicine

Volumn 167, Issue 12, 2007, Pages 1284-1290

  Hollander, Priscilla ^a   Yu, Dahong ^b   Chou, Hubert S ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; GELATINASE B; HEMOGLOBIN; INSULIN; ROSIGLITAZONE;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; EDEMA; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LOW DRUG DOSE; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 34347239997     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.167.12.1284     Document Type: Article

References (32)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
3. Fan T, Koro CE, Fedder DO, Bowlin SJ. Ethnic disparities and trends in glycemic control among adults with type 2 diabetes in the U.S. From 1988 to 2002. Diabetes Care. 2006;29:1924-1925.
4. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49): UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
5. Buse JB, Gumbiner B, Mathias NP, et al. Troglitazone use in insulin-treated type 2 diabetic patients: the Troglitazone Insulin Study Group. Diabetes Care. 1998;21:1455-1461.
6. UK Prospective Diabetes Study (UKPDS) Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
7. Yki-Järvinen H. Combination therapy with insulin and oral agents: optimizing glycemic control in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2002;18(suppl 3):S77-S81.
8. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
9. Carey DG, Cowin GJ, Galloway GJ, et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obes Res. 2002;10:1008-1015.
10. Strowig SM, Aviles-Santa ML, Raskin P. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. Diabetes Care. 2002;25:1691-1698.
11. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes. 1999;48:2414-2421.
12. Walter H, Lubben G. Potential role of oral thiazolidinedione therapy in preserving beta-cell function in type 2 diabetes mellitus. Drugs. 2005;65:1-13.
13. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care. 2004;27:2585-2589.
14. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med. 2004;21:568-576.
15. Viberti GC. Rosiglitazone: potential beneficial impact on cardiovascular disease. Int J Clin Pract. 2003;57:128-134.
16. Waugh J, Keating GM, Plosker GL, et al. Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs. 2006;66:85-109.
17. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226-1232.
18. Mattoo V, Eckland D, Widel M, et al. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study. Clin Ther. 2005;27:554-567.
19. Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251-257.
20. Schwartz S, Raskin P, Fonseca VA, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus: Troglitazone and Exogenous Insulin Study Group. N Engl J Med. 1998;338:861-866.
21. Davidson JA, Perez A, Zhang J. Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study. Diabetes Obes Metab. 2006;8:164-174.
22. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2002;25(suppl 1):S5-S20.
23. Kahn SE, Haffner S, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-2443.
24. Nathan DM. Thiazolidinediones for initial treatment of type 2 diabetes? N Engl J Med. 2006;355:2477-2480.
25. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-263.
26. Wong TY, Szeto CC, Chow KM, et al. Rosiglitazone reduces insulin requirement and C-reactive protein levels in type 2 diabetic patients receiving peritoneal dialysis. Am J Kidney Dis. 2005;46:713-719.
27. Freed MI, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(suppl 1):A267.
28. Fonseca VA, Theuma P, Mudaliar S, et al. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications. 2006;20:14-20.
29. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106:679-684.
30. Dormandy JA, Charbonnel B, Eckland D, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
31. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia. 2005;48:1726-1735.
32. Sobel BE, Frye R, Detre KM. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2003;107:636-642.